Page 19 - Bharat Biotech

Covid-19: CSIR-IICT played key role in developing adjuvant for Covaxin

The process technology developed by the CSIR, IICT for the agonist molecule is playing an important role in the production of adjuvant for Bharat Biotech's COVID-19 vaccine Covaxin, the CSIR said

Bharat Biotech signs deal to send 20 mn Covaxin doses to Brazil

Shipments to be made during second and third quarters of current calendar

Bharat Biotech signs pact to supply 20 mn doses of Covaxin to Brazil

The supply is slated to take place in the second and third quarters of current year

Ukraine keen on Bharat Biotech's Covaxin, sends team to negotiate supply

Three-member delegation led by nation's health minister visits Hyderabad unit, discusses timeline for delivery of shots on priority, and prospects of a tie-up for teh firm;s intranasal vaccine

Top headlines: New corporate pay structure, mapping deregulation, and more

From investor charter presented in the Union Budget to correction in gold prices, here are the top headlines on Tuesday morning

Can re-engineer Covaxin to beat South African variant: Bharat Biotech

Other vaccine makers, such as Hyderabad-based Biological E, too, have started working on different strains.

Bharat Biotech to have phase 3 efficacy data for Covaxin in 2 weeks

The restricted emergency use allowed by the regulator was based on phase 2 safety and immunogenicity studies, as well as data from monkey trials

Madras HC notice to Centre on plea to declare Covishield vaccine as unsafe

The petitioner, 41-year old Asif Riaz, also sought an interim injunction restraining the Central government and the Drugs Controller General of India from continuing with administering Covishield

Bharat Biotech pursues Covid-19 vaccine approval in over 40 countries

The company has also entered into an agreement with U.S. drug developer Ocugen Inc for the commercialization of COVAXIN in the United States, which has seen the most number of infections in the world

Top headlines: Sebi eases listing rules for large IPOs, Bitcoin hits record

A month into the Covid-19 immunisation drive, as many as 21 states and Union Territories (UTs) have not administered a single shot of Covaxin from Bharat Biotech. Read top news with Business Standard

States shying away from administering Bharat Bio's Covid-19 vaccine Covaxin

A month on, 21 states and UTs have not administered a single shot of the vaccine

More Covid vaccine supplies lined up as India gets ready for Phase 3 drive

Bharat Bio may add 200 mn doses if needed; Serum to have 2.5 mn capacity by year-end

Chhattisgarh rejects Bharat Biotech vaccine approved without efficacy data

The developers and India's drug regulator, however, say the vaccine is safe and effective based on early and intermediate studies

A shot at recovery

Vaccine delivery needs to move beyond govt control

Top headlines: Setback for Amazon, India to appeal against Cairn verdict

On Monday, the central bank said it would buy bonds worth Rs 20,000 crore from the secondary markets on Wednesday. Read top news with Business Standard here

Serum Institute, Bharat Biotech ramp up Covid-19 vaccine export plan

Home-grown firms get new orders: 10 million for SII, 4.5 million for Bharat Bio

Bharat Biotech inks pact to commercialise Covid-19 vaccine Covaxin in US

Ocugen, a Nasdaq-listed firm, focuses on developing and commercialising gene therapies to cure blindness diseases

Supply order for Covishield was placed after drug regulator's nod: Govt

The Rajya Sabha was informed about this on Tuesday

SII, Bharat Biotech welcome enhanced focus on health in Budget 2021

Serum Institute of India and Bharat Biotech applauded the government's increased allocation for the healthcare sector and on providing Rs 35,000 crore towards Covid-19 vaccination in 2021-22 fiscal.

Bharat Biotech hails Rs 35,000 cr budget allocation for Covid vaccination

The indigenous Covid-19 vaccine Covaxin and Oxford's Covishield are being produced in the country